Risk of different histological types of postmenopausal breast cancer by type and regimen of menopausal hormone therapy.
about
The breast cancer epidemic: 10 factsMortality and recurrence risk in relation to the use of lipid-lowering drugs in a prospective breast cancer patient cohortGenetic modifiers of menopausal hormone replacement therapy and breast cancer risk: a genome-wide interaction study.Breast cancer epidemic in the early twenty-first century: evaluation of risk factors, cumulative questionnaires and recommendations for preventive measures.Characteristics and recent evolution of menopausal hormone therapy use in a cohort of Swedish womenUse of menopausal hormone therapy and risk of ductal and lobular breast cancer among women 55-74 years of ageA replicated association between polymorphisms near TNFα and risk for adverse reactions to radiotherapyRisk factors of breast cancer: a systematic review and meta-analysis.MicroRNA related polymorphisms and breast cancer risk.Polymorphisms in the gene regions of the adaptor complex LAMTOR2/LAMTOR3 and their association with breast cancer riskConfirmation of the reduction of hormone replacement therapy-related breast cancer risk for carriers of the HSD17B1_937_G variant.Assessing interactions between the associations of common genetic susceptibility variants, reproductive history and body mass index with breast cancer risk in the breast cancer association consortium: a combined case-control study.Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies.Risk of breast cancer by type of menopausal hormone therapy: a case-control study among post-menopausal women in France.A genome-wide "pleiotropy scan" does not identify new susceptibility loci for estrogen receptor negative breast cancer.Lobular breast cancer: incidence and genetic and non-genetic risk factors.Estimated enterolignans, lignan-rich foods, and fibre in relation to survival after postmenopausal breast cancer.Coffee consumption modifies risk of estrogen-receptor negative breast cancer.Serum 25-hydroxyvitamin D and postmenopausal breast cancer survival: a prospective patient cohort studyA polymorphism in the base excision repair gene PARP2 is associated with differential prognosis by chemotherapy among postmenopausal breast cancer patients.11q13 is a susceptibility locus for hormone receptor positive breast cancer.Interaction between common breast cancer susceptibility variants, genetic ancestry, and nongenetic risk factors in Hispanic women.Identification of shared and unique susceptibility pathways among cancers of the lung, breast, and prostate from genome-wide association studies and tissue-specific protein interactions.Polymorphisms of Phase I and Phase II Enzymes and Breast Cancer Risk.Dietary patterns and survival in German postmenopausal breast cancer survivorsEvidence of gene-environment interactions between common breast cancer susceptibility loci and established environmental risk factorsThe UGT1A6_19_GG genotype is a breast cancer risk factor.Risk factors for specific histopathological types of postmenopausal breast cancer in the NIH-AARP Diet and Health Study.A genome-wide association study to identify genetic susceptibility loci that modify ductal and lobular postmenopausal breast cancer risk associated with menopausal hormone therapy use: a two-stage design with replication.The pharmacogenomics of sex hormone metabolism: breast cancer risk in menopausal hormone therapy.Effects of omega-3 fatty acids on progestin stimulation of invasive properties in breast cancer.Benefits and risks during HRT: main safety issue breast cancer.Modeling Variables With a Spike at Zero: Examples and Practical Recommendations.Postmenopausal hormone therapy and the risk of breast cancer in Norway.A Comprehensive Multistate Model Analyzing Associations of Various Risk Factors With the Course of Breast Cancer in a Population-Based Cohort of Breast Cancer Cases.Relationship between menopausal hormone therapy and mortality after breast cancer The MARIEplus study, a prospective case cohort.Do the dose or route of administration of norethisterone acetate as a part of hormone therapy play a role in risk of breast cancer: national-wide case-control study from Finland.Association of pre-diagnosis physical activity with recurrence and mortality among women with breast cancer.Circulating 25-hydroxyvitamin D and postmenopausal breast cancer survival: Influence of tumor characteristics and lifestyle factors?Serum enterolactone and postmenopausal breast cancer risk by estrogen, progesterone and herceptin 2 receptor status.
P2860
Q22299214-83EA26E8-562B-49AA-BD44-ABFA739563C7Q28533813-31239912-82DD-4EDB-8228-AA703A80146BQ29417068-834FB022-1F93-431E-AA26-027533726577Q30248838-C7EA8837-8FFA-4E47-AD96-50F67D825F19Q33710365-31DEE352-0C58-452E-8DE9-FDE5C08D53C4Q33823771-3B4B397B-E104-4682-ADD1-95CB89B80773Q34286293-3A70239D-E077-4115-9E24-67353F0F4E59Q34346863-593573F8-7A88-4D97-A05A-9AF1C2E02549Q34497352-123277D1-6074-47D0-A294-B09216125816Q34558708-4ABC25B2-8147-4E2E-9B72-795B59E1B433Q34594697-723E9101-43C4-461F-98ED-F312ED68ECC2Q34613673-C2AD9CA9-8687-40B2-9273-450742953D36Q35022847-49F7D0B6-D176-40DC-9627-8CB26BF51EB5Q35040736-3EE82833-A237-4A14-ABBB-21652BF8089EQ35093501-0B5F6840-9247-42D2-B920-7D358D12F650Q35170028-00A96C00-5377-4179-B0F6-BB6A224A7BF1Q35527144-31604D55-94D3-490E-B6C6-CCA28A380D1FQ35558033-0090FBDF-783F-47F0-BC3D-4D07822DC5C2Q35608695-ACD00D8E-2057-416C-9A23-4240EC2E739AQ35870483-A56BD858-8ECF-41E9-8C62-D3C98D056E4AQ36016386-E635AD41-9617-4999-8231-3E36222D12A2Q36249029-301094DB-B2A0-45CF-A239-BF517B9D226BQ36331604-4B9B8393-7A9E-455F-8CA6-F74632FC9CAFQ36429795-92AB2B3E-F589-4F37-899B-44E69868AB91Q36557835-6605C2B7-4CDA-4CCA-A05E-BCAD7645F8E5Q36720821-ADBE1C8C-8F06-485A-8A27-CD38EE4A74CFQ36917100-23AC49C8-8E16-4925-822F-9C64FD0AA2F6Q37055548-DC1B32B5-2470-433B-8258-AC39399D51DAQ37192589-D16B3F97-5B68-4210-AC5F-B46CE207BB30Q38003702-959206B4-DF4D-4A8E-AD99-BD18C00C9A55Q38029548-AF1C1B84-3155-4726-A544-B2CE518EB11EQ38471535-A16D7523-EB7B-4B48-BAF2-3AE3CF62BA9AQ38860482-264D73EC-3CBA-4A9E-A0DD-A7C38B122450Q40626144-DC42905B-0A50-4E71-8798-AE5105E7BEABQ40943174-C8164C2E-2B02-48C1-96CE-F08FD8445D63Q41065061-E09C7F44-554F-40E2-9BE0-030C0ADA2DFFQ43254264-446F3B5B-36F7-4C00-B4B3-20EB8296037DQ43488772-28FA50D6-6F41-4189-8E67-76717A1CE7A1Q43519004-33DD43D0-3F52-463F-9A37-1C0AFFFB3E68Q43561419-F00394B7-1A36-4A71-B3E1-41EC2F1592AB
P2860
Risk of different histological types of postmenopausal breast cancer by type and regimen of menopausal hormone therapy.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Risk of different histological ...... of menopausal hormone therapy.
@en
Risk of different histological ...... of menopausal hormone therapy.
@nl
type
label
Risk of different histological ...... of menopausal hormone therapy.
@en
Risk of different histological ...... of menopausal hormone therapy.
@nl
prefLabel
Risk of different histological ...... of menopausal hormone therapy.
@en
Risk of different histological ...... of menopausal hormone therapy.
@nl
P2093
P2860
P50
P356
P1476
Risk of different histological ...... of menopausal hormone therapy.
@en
P2093
Elke Mutschelknauss
Gunter Bastert
Jürgen Berger
Silke Kropp
Stefan Hentschel
Tracy Slanger
Wilhelm Braendle
P2860
P304
P356
10.1002/IJC.23655
P577
2008-08-01T00:00:00Z